Mon, Apr 21, 2014, 9:22 AM EDT - U.S. Markets open in 8 mins.

Recent

% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

  • tipper3046 tipper3046 Mar 27, 2013 8:40 AM Flag

    "Biotech Industry Looks To Benefit From FDA's New 'Breakthrough' Designation" - March 14, 2013

    http://finance.yahoo.com/news/biotech-industry-looks-benefit-fdas-122000713.html

    In part -
    The FDA's new "Breakthrough" product designation allows new drugs to win approval after just a single round of testing , instead of the usual three. A total of three promising experimental medicines, have been assigned the new status so far, while an additional 18 drugs have applied. The new designation follows three other programs -- Fast Track, Priority Review and Accelerated Approval -- each of which were designed to help bring crucial new drugs to market in a shorter amount of time.

    "A 'Breakthrough' drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments", said Janet Woodcock, director of FDA's Center For Drug Evaluation & Research.

    Is Neuralstem (CUR) one of the "18 drugs" that have applied?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CUR
3.79+0.08(+2.11%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AstraZeneca PLC
NYSEThu, Apr 17, 2014 4:00 PM EDT
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT